第一条 为规范江苏澳洋健康产业股份有限公司（以下简称"公司"）董事 及高级管理人员的选聘，优化董事会组成，完善公司治理结构，根据《中华人民 共和国公司法》（以下简称"《公司法》"）、《上市公司治理准则》《江苏澳洋健康 产业股份有限公司章程》（以下简称"《公司章程》"）及其他有关规定，公司特设 立董事会提名委员会（以下简称"提名委员会"），并制订本细则。 江苏澳洋健康产业股份有限公司 董事会提名委员会工作细则 二〇二五年十二月 江苏澳洋健康产业股份有限公司 董事会提名委员会工作细则 第一章 总则 第二条 提名委员会是董事会依据相应法律法规设立的专门工作机构，对董 事会负责并报告工作，主要负责对公司董事和高级管理人员的人选、选择标准和 程序进行研究并提出建议。 第二章 人员组成 第三条 提名委员会成员由三名董事组成，其中独立董事两名。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者三分之一以 上（含三分之一）的全体董事提名，并由董事会选举产生。 第五条 提名委员会设主任委员（召集人）一名，由委员会委员选举一名独 立董事委员担任，负责主持委员会工作。 第六条 提名委员会任期与董事会任期一致，委员任期届满， ...

第九届董事会第八次会议决议公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-37 江苏澳洋健康产业股份有限公司 第九届董事会第八次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）第九 届董事会第八次会议于 2025 年 11 月 22 日以通讯方式发出会议通知，于 2025 年 12 月 2 日下午在公司会议室以现场结合通讯方式召开。会议应出席董事 9 名， 实际出席会议董事 9 名。公司监事及高管列席了会议。会议由公司董事长沈学如 先生主持，符合《公司法》及公司《章程》的有关规定。会议经认真审议，通过 如下议案： 一、审议通过《关于提前换届选举第十届董事会非独立董事的议案》 鉴于公司控股股东变更，根据《公司法》和公司《章程》等有关规定，经公 司董事会提名委员会进行资格审查后，公司控股股东张家港悦升科技合伙企业 （有限合伙）（以下简称"悦升科技"）拟提名高彦、席国平、卢平、季超为公 司第十届董事会非独立董事候选人；经公司股东澳洋集团有限公司（以下简称"澳 ...

Group 1 - The core viewpoint of the article highlights a significant movement in the elderly care sector, particularly with stocks like Yuexin Health experiencing a surge due to regulatory developments [1][3] - Yuexin Health (002162) reached a limit-up price of 5.31 CNY per share, with a price-to-earnings ratio of 11187.52 and a total market capitalization of 4.884 billion CNY [1] - The surge in the elderly care sector is attributed to a joint press conference by the State Administration for Market Regulation and the Ministry of Civil Affairs, which provided insights into the "Guidelines for the Construction of the Elderly Care Service Standard System (2025 Edition)" [1] Group 2 - Yuexin Health operates under a light asset model, focusing on the management and operation of public-private partnership projects, while also engaging in strategic investments and acquisitions [3] - The company has established a comprehensive service system covering institutional elderly care, community services, and smart elderly care, with several benchmark projects already implemented [3] - Notable projects include the Shanghai Fengxian Jinhai Yuexin Nursing Home and the Jiangsu Suqian Yuexin·Sihong Elderly Care Center, with the Shanghai project receiving a rental subsidy of 3 million CNY annually as part of the first batch of pilot projects under the "Housing Rental Regulations" [3]

Core Insights - The medical services sector experienced a slight increase of 0.45% on November 26, with Lanwei Medical leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Medical Services Sector Performance - Lanwei Medical (301060) closed at 10.79, up 7.90%, with a trading volume of 410,000 shares and a transaction value of 444 million yuan [1] - Sunshine Nuohuo (688621) closed at 68.55, up 7.63%, with a trading volume of 78,800 shares and a transaction value of 537 million yuan [1] - ST Zhongzhu (600568) closed at 2.70, up 5.06%, with a trading volume of 853,900 shares and a transaction value of 230 million yuan [1] - Chengdu Xian Dao (688222) closed at 23.40, up 2.45%, with a trading volume of 110,000 shares and a transaction value of 260 million yuan [1] - Other notable performers include Yaokang Bio (688046) and Kailai Ying (002821), with increases of 2.03% and 2.02% respectively [1] Capital Flow Analysis - The medical services sector saw a net inflow of 307 million yuan from institutional investors, while retail investors experienced a net outflow of 219 million yuan [2] - Major stocks like Yao Ming Kang De (603259) and Chengda Pharmaceutical (301201) had significant capital movements, with net inflows of 26.1 million yuan and 10.4 million yuan respectively [3] - Conversely, stocks like Bi De Pharmaceutical (688073) and Haochen Medical (002622) faced net outflows of 4.6% and 2.07% respectively [2][3]

Group 1 - The core viewpoint of the news is that Aoyang Health has shown fluctuations in stock performance, with a year-to-date increase of 35.14% but a recent decline in the last five trading days by 5.58% [1] - As of November 25, Aoyang Health's stock price was 4.23 CNY per share, with a market capitalization of 3.239 billion CNY [1] - The company has experienced a net inflow of main funds amounting to 3.5156 million CNY, with significant buying and selling activities noted [1] Group 2 - For the period from January to September 2025, Aoyang Health reported operating revenue of 1.36 billion CNY, a year-on-year decrease of 9.39%, while the net profit attributable to shareholders was 40.1137 million CNY, reflecting a year-on-year increase of 3.71% [2] - The company has a total of 58,300 shareholders as of September 30, which is a decrease of 10.91% from the previous period, while the average circulating shares per person increased by 12.24% to 13,121 shares [2] - Aoyang Health has cumulatively distributed dividends of 26.1 million CNY since its A-share listing, with no dividends distributed in the last three years [3]

关于持股5%以上股东及其一致行动人部分股份解除质押和股份质押的公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-36 江苏澳洋健康产业股份有限公司 关于持股 5%以上股东及其一致行动人部分股份解除 质押和股份质押的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 一、股东股份解除质押的基本情况 股东名 称 是否为控股股东 或第一大股东及 其一致行动人 本次解除质 押股数(股) 占其所持 股份比例 占公司总 股本比例 质押起 始日 解除质 押日 质权人 质押用 途 澳洋集 团有限 公司 否 25,000,000 30.41% 3.26% 2024/11 /20 2025/1 1/21 中国光大 银行股份 有限公司 无锡分行 担保 | | | | | | | | | | 限合伙） | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 澳洋集团 有限公司 | 否 | 25,000,000 | 30.41% | 3.26% | 否 | 否 ...

Market Overview - The medical services sector increased by 1.65% on November 24, with Chengdu XianDao leading the gains [1] - The Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] Stock Performance - Notable stock performances include: - Chengda Pharmaceutical (301201) closed at 46.40, down 3.25% with a trading volume of 129,800 shares and a turnover of 613 million yuan - Yaner Eye Hospital (300015) closed at 11.55, down 1.20% with a trading volume of 684,000 shares and a turnover of 797 million yuan - International Medical (000516) closed at 4.65, up 0.87% with a trading volume of 119,800 shares and a turnover of 55.6 million yuan [1] Capital Flow - The medical services sector experienced a net outflow of 170 million yuan from institutional investors and 158 million yuan from retail investors, while retail investors saw a net inflow of 327 million yuan [3] - Key capital flows for specific stocks include: - WuXi AppTec (603259) had a net inflow of 251 million yuan from institutional investors but a net outflow of 91.72 million yuan from retail investors - Tiger Med (300347) saw a net inflow of 62.56 million yuan from institutional investors but a net outflow of 6.44 million yuan from retail investors [3]

Core Viewpoint - The report highlights the growth trends in China's synthetic fiber industry, indicating a production increase and positive market outlook for the coming years [1]. Industry Summary - As of September 2025, China's synthetic fiber production reached 6.77 million tons, reflecting a year-on-year growth of 4.8% [1]. - Cumulatively, from January to September 2025, the total production of synthetic fibers in China was 59.512 million tons, marking a cumulative growth of 5.6% [1]. - The data is sourced from the National Bureau of Statistics and compiled by Zhiyan Consulting, a leading industry research institution in China [1]. Company Summary - Listed companies in the synthetic fiber sector include Hengyi Petrochemical (000703), Rongsheng Petrochemical (002493), Xin Fengming (603225), Tongkun Co., Ltd. (601233), Hengli Petrochemical (600346), Jilin Chemical Fiber (000420), Huafeng Chemical (002064), Aoyang Health (002172), Taihe New Materials (002254), and Jiangnan High Fiber (600527) [1]. - The report emphasizes the importance of these companies in the context of the industry's growth and market dynamics [1].

Core Viewpoint - The report highlights the growth of China's chemical fiber industry, with a projected production increase and positive market outlook from 2025 to 2031 [1] Industry Summary - As of September 2025, China's chemical fiber production reached 7.45 million tons, marking a year-on-year growth of 4.8% [1] - Cumulatively, from January to September 2025, the total production of chemical fibers in China was 65.156 million tons, reflecting a cumulative growth of 5.6% [1] - The data indicates a steady upward trend in production, suggesting a robust market environment for the chemical fiber sector [1] Company Summary - Listed companies in the chemical fiber sector include Xinxiang Chemical Fiber, Hengli Petrochemical, Huafeng Superfiber, Rongsheng Petrochemical, Jilin Chemical Fiber, Tongkun Co., Zhongtai Chemical, Nanjing Chemical Fiber, Taihe New Materials, and Aoyang Health [1] - The report by Zhiyan Consulting provides insights into the operational status and investment prospects of the chemical fiber industry in China [1]

Core Insights - The high-pressure oxygen chamber concept has seen a decline of 0.21%, ranking among the top declines in concept sectors as of the market close on November 13 [1] - Within the sector, companies like Innovation Medical and International Medicine experienced significant declines, while six stocks saw price increases, with Dahu Co., Aoyang Health, and Samsung Medical leading the gains [1] Market Performance - The top-performing concept sectors today include: - Fluorochemical concept: +4.50% - Organic silicon concept: +4.47% - Sodium-ion battery: +4.47% - Lead metal: +4.27% - Phosphorus chemical: +4.25% [2] - The high-pressure oxygen chamber sector experienced a net outflow of 149 million yuan, with eight stocks seeing net outflows [2] Fund Flow Analysis - The stocks with the highest net outflows in the high-pressure oxygen chamber sector include: - Samsung Medical: -60.80 million yuan - Innovation Medical: -57.39 million yuan - International Medicine: -12.53 million yuan [2] - Conversely, the stocks with the highest net inflows include: - Yingkang Life: +10.12 million yuan - Hangyang Co.: +9.74 million yuan [2] Stock Performance - Key stock performances in the high-pressure oxygen chamber sector: - Samsung Medical: +0.37%, turnover rate: 2.18% - Innovation Medical: -2.00%, turnover rate: 13.41% - International Medicine: -0.80%, turnover rate: 1.13% [2]